

Atsushi Aruga

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11284581/publications.pdf>

Version: 2024-02-01

25
papers

723
citations

623734

14
h-index

642732

23
g-index

25
all docs

25
docs citations

25
times ranked

1053
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical utilization of postoperative dendritic cell vaccine plus activated T cell transfer in patients with intrahepatic cholangiocarcinoma. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2012, 19, 171-178.	2.6	87
2	Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma. <i>Cancer</i> , 2002, 94, 1770-1776.	4.1	69
3	Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer. <i>Journal of Translational Medicine</i> , 2014, 12, 61.	4.4	66
4	Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 2224-2231.	7.0	63
5	Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUUS-PC study. <i>Cancer Science</i> , 2017, 108, 73-80.	3.9	54
6	Different cytokine profiles released by CD4+ and CD8+ tumor-draining lymph node cells involved in mediating tumor regression. <i>Journal of Leukocyte Biology</i> , 1997, 61, 507-516.	3.3	47
7	Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 970-976.	3.3	47
8	Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterizations and clinical utilization. <i>International Journal of Cancer</i> , 1991, 49, 19-24.	5.1	45
9	Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. <i>Oncolmmunology</i> , 2013, 2, e27010.	4.6	45
10	Immunological monitoring of anticancer vaccines in clinical trials. <i>Oncolmmunology</i> , 2013, 2, e26012.	4.6	38
11	Clinical evaluation of therapeutic cancer vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1049-1057.	3.3	28
12	Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 36.	8.6	24
13	Phase I clinical trial of a peptide vaccine combined with tegafur-uracil plus leucovorin for treatment of advanced or recurrent colorectal cancer. <i>Oncology Reports</i> , 2013, 29, 951-959.	2.6	22
14	Enhanced adjuvant effect of granulocyte-macrophage colony-stimulating factor plus interleukin-12 compared with either alone in vaccine-induced tumor immunity. <i>Cancer Gene Therapy</i> , 1999, 6, 89-95.	4.6	18
15	Cytokines as an adjuvant to tumor vaccines: Efficacy of local methods of delivery. <i>Annals of Surgical Oncology</i> , 1997, 4, 579-585.	1.5	14
16	Fever-range whole-body heat treatment stimulates antigen-specific T-cell responses in humans. <i>Immunology Letters</i> , 2014, 162, 256-261.	2.5	14
17	Concurrent Induction of CD4+ and CD8+ T Cells During Tumor Growth with Antitumor Reactivity in Adoptive Immunotherapy. <i>Journal of Immunotherapy</i> , 1997, 20, 138-145.	2.4	9
18	RT-qPCR analysis of the tumor antigens TOMM34 and RNF43 in samples extracted from paraffin-embedded specimens of colorectal cancer. <i>Oncology Letters</i> , 2017, 14, 2281-2287.	1.8	9

#	ARTICLE	IF	CITATIONS
19	CD95-Mediated Tumor Recognition by CD4+ Effector Cells in a Murine Mammary Model. Journal of Immunotherapy, 2000, 23, 225-234.	2.4	6
20	Approaches to improve development methods for therapeutic cancer vaccines. Immunology Letters, 2015, 164, 100-108.	2.5	6
21	Establishment and characterization of liver metastatic model of human hepatoma in nude mice. International Hepatology Communications, 1993, 1, 138-145.	0.7	5
22	Vaccination of biliary tract cancer patients with four peptides derived from cancer-testis antigens. OncoImmunology, 2013, 2, e24882.	4.6	5
23	Separation Methods of T Cells, Natural Killer, and Dendritic Cells from Peripheral Blood of Cancer Patients using Interleukin-2 and Functional Analysis of Natural Killer Cells after Separation. Immunopharmacology and Immunotoxicology, 2007, 29, 31-47.	2.4	2
24	Î±Î²-T Cells. , 2016, , 63-73.		0
25	Multidisciplinary treatment for multiple hepatocellular carcinoma. , 1992, , 335-342.		0